Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study
Open Access
- 1 March 2008
- Vol. 94 (3) , 278-283
- https://doi.org/10.1136/hrt.2007.128991
Abstract
Background: Cardiac resynchronisation therapy (CRT) improves symptoms and prognosis in patients with heart failure and cardiac dyssynchrony. Guidelines from the National Institute of Health and Clinical Excellence in the United Kingdom recommend CRT for patients with recent or persistent moderate or severe symptoms of heart failure. This analysis investigated whether the severity of symptoms was an important determinant of the prognostic benefits of CRT. Methods: In CARE-HF, patients with left ventricular ejection fraction ⩽35% and markers of cardiac dyssynchrony who were, in the investigators’ opinion, in New York Heart Association (NYHA) class III/IV were randomly assigned to pharmacological treatment alone or with addition of CRT. This analysis investigated whether the severity of symptoms reported by patients, using Likert Scales from the EuroHeart Failure Questionnaire and self-assessed NYHA class, influenced prognosis and the response to CRT. Results: Of 813 patients, 175 (21.5%) assessed themselves to be in NYHA class I or II. These patients also reported less severe symptoms and better quality of life than patients who assessed themselves to be in NYHA class III or IV. No statistical interaction was observed between the severity of symptoms assessed in several ways and the benefits of CRT on morbidity and mortality. Conclusions: The severity of symptoms was not an important determinant of the prognostic effects of CRT in patients with moderate or severe LVSD and markers of dyssynchrony in the CARE-HF study. This finding requires confirmation in an adequately powered prospective randomised controlled trial in patients with milder symptoms.Keywords
This publication has 13 references indexed in Scilit:
- Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]European Heart Journal, 2006
- Cardiac resynchronisation for patients with heart failure due to left ventricular systolic dysfunction — a systematic review and meta‐analysisEuropean Journal of Heart Failure, 2006
- Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)European Heart Journal, 2005
- The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart FailureNew England Journal of Medicine, 2005
- Baseline characteristics of patients recruited into the CARE-HF studyEuropean Journal of Heart Failure, 2005
- Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart FailureCirculation, 2004
- Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart FailureNew England Journal of Medicine, 2004
- A Description of the Clinical Characteristics at Baseline of Patients Recruited into the Carvedilol or Metoprolol European Trial (COMET)Cardiovascular Drugs and Therapy, 2004
- Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmiasJournal of the American College of Cardiology, 2003
- The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐pointsEuropean Journal of Heart Failure, 2001